Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Corcept Therapeutics (CORT) over the last 13 years, with Sep 2025 value amounting to $108.4 million.

  • Corcept Therapeutics' Accumulated Expenses rose 36.47% to $108.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.4 million, marking a year-over-year increase of 36.47%. This contributed to the annual value of $90.7 million for FY2024, which is 75.68% up from last year.
  • Per Corcept Therapeutics' latest filing, its Accumulated Expenses stood at $108.4 million for Q3 2025, which was up 19.08% from $91.1 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Accumulated Expenses registered a high of $108.4 million during Q3 2025, and its lowest value of $18.0 million during Q1 2021.
  • Over the past 3 years, Corcept Therapeutics' median Accumulated Expenses value was $69.6 million (recorded in 2023), while the average stood at $71.8 million.
  • In the last 5 years, Corcept Therapeutics' Accumulated Expenses declined by 8.12% in 2021 and then skyrocketed by 136.75% in 2023.
  • Over the past 5 years, Corcept Therapeutics' Accumulated Expenses (Quarterly) stood at $27.7 million in 2021, then grew by 11.33% to $30.8 million in 2022, then spiked by 67.63% to $51.6 million in 2023, then soared by 75.68% to $90.7 million in 2024, then surged by 36.47% to $108.4 million in 2025.
  • Its Accumulated Expenses stands at $108.4 million for Q3 2025, versus $91.1 million for Q2 2025 and $88.9 million for Q1 2025.